Skip to content

Does Visceral Manipulation Works in Treating Functional Dyspepsia?

Does Visceral Manipulation Works in Treating Functional Dyspepsia? A Randomized Study

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01021475
Enrollment
50
Registered
2009-11-30
Start date
2009-11-30
Completion date
Unknown
Last updated
2009-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia

Keywords

Functional Dyspepsia, Visceral Manipulation

Brief summary

The goal of this study is to determine if Visceral Manipulation (VM) is effective in treating Functional Dyspepsia in addition to drug therapy. Null hypothesis is that VM does not influence FD symptoms.

Detailed description

50 patients with Functional Dyspepsia (FD) diagnosed by General Practitioners are randomized in two therapy group: 1) drug only group and 2) drug + Visceral Manipulation group. Group 1 receive drug therapy for 4 weeks, Group 2 receive drug therapy for 4 weeks and 4 Visceral Manipulation visits with weekly frequency (visit 1 at day 1 of drug therapy). FD symptoms are recorded with VAS at baseline and after 1 and 4 weeks of therapy, and after 8 weeks (4 weeks after the finish of all therapies).

Interventions

Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.

DRUGPPIs and/or Domperidone

Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks

Sponsors

International College of Osteopathic Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Functional Dyspepsia

Exclusion criteria

* Diabetes Mellitus * Mental disturbance * Thyroid gland dysfunction * Intestinal, liver and biliary tract disease * Concurrent medications that could interact with GI function * Positive Helicobacter Pylori status

Design outcomes

Primary

MeasureTime frame
FD symptoms: Bothersome postprandial fullness / Early satiation / Epigastric pain / Epigastric burningbaseline, 1, 4 and 8 weeks after therapy start

Countries

Italy

Contacts

Primary ContactMassimo Rossi, DO B.Sc (Student)
massimo@rossimassimo.com00393929517349

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026